10-Q: CDT Equity Reports Q3 Loss Amid Strategic Shift to AI Biotech

CDT Equity Inc. reported a net loss of $7.1 million for Q3 2025 and $17.9 million for the nine months ended September 30, 2025, while advancing its data-driven biotech and digital asset treasury management strategy.

Summary

• CDT Equity Inc. reported a net loss of $7.1 million for the three months ended September 30, 2025, compared to $6.5 million for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss was $17.9 million, an increase from $15.4 million in the prior year period.
• Cash and cash equivalents increased significantly to $3.8 million as of September 30, 2025, from $0.6 million at December 31, 2024.
• The company adopted ASU 2023-08 and held approximately $1.0 million in Bitcoin as digital assets as of September 30, 2025.
• Research and development expenses decreased by 50% to $1.5 million for the three months ended September 30, 2025, but increased by 33% to $4.3 million for the nine months ended September 30, 2025.
• General and administrative expenses increased by 102% to $5.5 million for the three months ended September 30, 2025, and by 30% to $11.3 million for the nine months ended September 30, 2025.
• The company completed three reverse stock splits in 2025: 1-for-100 (January 24), 1-for-15 (May 19), and 1-for-8 (October 10).
• An 'at-the-market' (ATM) offering program raised $18.0 million (net of commissions) for the nine months ended September 30, 2025, with the full $23.9 million program utilized post-period.
• The company faces substantial doubt about its ability to continue as a going concern due to accumulated deficit and expected future operating losses.
• Material weaknesses in disclosure controls and procedures were identified and not yet remediated as of September 30, 2025.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including increased net losses, a growing accumulated deficit, and a stated 'going concern' risk. While strategic shifts and capital raising efforts are underway, the current financial performance and internal control weaknesses present substantial concerns for investors. The exploration of a cryptocurrency treasury strategy introduces additional, non-traditional risk.

Positives

• Cash and cash equivalents significantly increased to $3.8 million as of September 30, 2025, from $0.6 million at December 31, 2024.
• Successfully raised $18.0 million (net) through the ATM program during the nine months ended September 30, 2025, with the full $23.9 million program utilized post-period.
• Regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, and transferred listing to The Nasdaq Capital Market.
• Strategic partnerships with Sarborg Limited for AI-powered disease mapping and cybernetic technology services, and Manoira Corporation for animal health applications, are advancing the company's asset portfolio.
• Acquired a diagnostic tool with alternative future use, capable of predictive modeling for delisted patents, which was capitalized at $0.4 million.
• Successfully settled a convertible promissory note payable for $0.7 million, resulting in a gain on debt extinguishment of $0.1 million.
• Reached an agreement with A.G.P. to waive $0.4 million of previously accrued interest on the A.G.P. Convertible Note, recorded as other income.

Negatives

• Net loss increased to $7.1 million for the three months ended September 30, 2025, from $6.5 million in the prior year, and to $17.9 million for the nine months ended September 30, 2025, from $15.4 million.
• Accumulated deficit grew to $47.0 million as of September 30, 2025, from $29.1 million at December 31, 2024.
• General and administrative expenses increased substantially by 102% for the three months and 30% for the nine months ended September 30, 2025, primarily due to legal fees, payroll, stock-based compensation, and travel.
• The company has identified substantial doubt about its ability to continue as a going concern for at least the next 12 months.
• Disclosure controls and procedures were not effective due to un-remediated material weaknesses.
• Ongoing legal proceedings, including a $0.4 million accrued legal contingency related to a claim from Strand Hanson Limited and a dispute with St George Street Capital over the AZD 1656 co-crystal patent.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to significant losses and negative operating cash flows.
• Dependence on additional funding through public or private equity/debt financings, with no assurance of availability on acceptable terms.
• Uncertainties related to pre-clinical and clinical outcomes, competitor products, and regulatory approvals in the pharmaceutical industry.
• Risks associated with related party transactions, including potential conflicts of interest and non-arms-length terms.
• Ongoing legal proceedings (Strand Hanson, St George Street Capital) could result in significant legal costs and diversion of management's attention.
• Inability to maintain ongoing compliance with Nasdaq listing rules, despite regaining compliance with some requirements.
• Risks associated with the digital asset treasury management strategy, including volatility of crypto assets and potential for losses.
• Reliance on third-party licensing agreements (e.g., AstraZeneca) where a breach or termination could materially affect the business.
• The company's estimates for operating costs may prove wrong, leading to faster depletion of capital resources.

Future Outlook

The company expects to generate operating losses and negative operating cash flows in the future, requiring additional funding beyond its current ATM program. Management is exploring strategic alternative paths to fundraising, including a shift to a digital asset treasury management company. The company plans to seek exits through third-party license deals following successful in vitro and in vivo pre-clinical trials for its therapeutic assets. It also intends to pursue additional relationships and partnerships to license deprioritized assets and focus on disorders with unmet treatment needs.

Management Comments

• Our name change to CDT Equity Inc. reflects the evolution of our strategy as a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships.
• CDT Equity's strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies with strong, supporting Phase I safety data.
• Through advanced co-crystallization and solid-form technologies developed at our Cambridge facilities, we aim to improve drug properties and have successfully extended the patent life of certain drugs by up to 20 years.
• Our collaboration with Sarborg enables us to apply proprietary algorithms utilizing AI-powered disease mapping to identify novel re-purposing opportunities across a database of more than 800 disease signatures.
• The Sarborg Agreement is designed to address longstanding challenges in the pharmaceutical sector, in particular by reducing human error in critical decision-making processes in both clinical development and asset identification.
• A further partnership with Manoira enables CDT Equity to expand the scope of its drug portfolio into the animal health market in a cost-efficient manner.
• The Board continues to evaluate a cryptocurrency treasury reserve strategy, collaborating with consultants to best advise a novel market which has seen significant recent activity and success for respective stakeholders.
• Operating with a lean disease-agnostic model, CDT Equity prioritizes speed, adaptability, and capital efficiency. We avoid the cost burden of late-stage clinical trials, focusing instead on high-leverage development strategies.
• Management has determined that it does not have sufficient cash and other sources of liquidity to fund its current business plan, raising substantial doubt regarding the company's ability to continue as a going concern.

Industry Context

CDT Equity is repositioning itself within the biotech and pharmaceutical industry by leveraging AI, solid-form chemistry, and asset repositioning to develop novel treatments. This strategy targets deprioritized clinical-stage compounds from larger pharmaceutical companies, aiming for faster, more capital-efficient development. The company's exploration of a digital asset treasury management strategy also places it at the intersection of biotech and emerging financial technologies, a less common approach in the traditional pharmaceutical sector. The focus on AI-powered disease mapping and extending patent life through co-crystallization aligns with broader industry trends seeking efficiency and intellectual property protection.

Comparison to Industry Standards

• The company's strategy of acquiring and repurposing deprioritized clinical assets from larger pharmaceutical companies like AstraZeneca (e.g., AZD1656, AZD5658, AZD5904) is a recognized model for smaller biotechs to build pipelines without the high upfront R&D costs of de novo drug discovery.
• The use of AI-powered disease mapping through partnerships like Sarborg Limited aligns with a growing trend in the pharmaceutical industry to accelerate drug discovery and identify new indications, a practice seen in companies like Recursion Pharmaceuticals or BenevolentAI.
• Extending patent life through solid-form technologies (co-crystallization) is a common strategy employed by pharmaceutical companies to maximize the commercial lifespan of drugs, similar to efforts by companies like Crystal Pharmatech.
• The company's lean, asset-agnostic model, avoiding late-stage clinical trial costs, contrasts with traditional large pharmaceutical companies that bear the full spectrum of R&D, but is typical for early-stage biotechs aiming for licensing deals post-preclinical or early clinical success.
• The exploration of a cryptocurrency treasury reserve strategy is highly unconventional for a biotech company and deviates significantly from standard industry financial management practices, which typically prioritize stable, liquid, and low-risk assets for treasury reserves.

Management Changes

Corporate Governance

Legal Proceedings

• A claim by Strand Hanson Limited for $2 million in advisory fees and 4,333 shares of Common Stock, with a $0.4 million liability accrued as probable and reasonably estimable. The trial concluded in October 2025, with a determination expected in Q1 2026.
• A dispute with St George Street Capital regarding the sole ownership of the AZD 1656 co-crystal patent, with formal complaints filed with the Intellectual Property Office. The company intends to vigorously defend against these claims, and the range of possible loss is not estimable or considered probable as of September 30, 2025.

Related Party Transactions

• Dr. Andrew Regan (CEO and Board member) incurred approximately $0.5 million in director travel expenses for the nine months ended September 30, 2025.
• Nirland (a related party) had its August 2024 Nirland Note and October 2024 Nirland Note fully repaid as of September 30, 2025, after conversions and cash repayments.
• SARBORG Limited (a related party, with Dr. Andrew Regan on its board) received $2.0 million for completed milestones under the Sarborg Service Agreement and $0.4 million for deliverables under the Sarborg Additional Agreement for the nine months ended September 30, 2025. The company also entered into First and Second Addendums for additional services, totaling $0.3 million and $0.4 million respectively.
• Manoira Corporation (controlled by Dr. Andrew Regan) entered into a Joint Development Agreement, receiving 19,349 shares of Common Stock valued at $0.4 million as consideration for evaluating CDT Assets in animal health.

Stakeholder Impact

• **Shareholders:** Significant dilution from ATM program and convertible note conversions. Increased accumulated deficit and going concern warning pose substantial risk to investment value. Share repurchase program was initiated then cancelled, indicating potential instability in capital management decisions. Stock-based compensation to management and directors could be viewed negatively if performance does not improve.
• **Employees:** Stock-based compensation awards (e.g., to CEO and CFO) are a positive for retention and motivation, but the going concern risk creates job insecurity.
• **Customers/Partners:** Strategic partnerships with Sarborg and Manoira aim to enhance drug development and market reach, potentially benefiting future customers through novel treatments. The AstraZeneca licensing agreement provides a pipeline of assets.
• **Creditors:** Convertible notes have been largely repaid or converted, reducing immediate debt obligations, but the going concern warning indicates elevated risk for remaining creditors.
• **Regulatory Authorities:** Nasdaq compliance issues were resolved, but ongoing material weaknesses in internal controls require attention and could lead to future scrutiny.

Next Steps

• Generate operating cash flows and secure additional funding through public or private equity or debt financings.
• Explore strategic alternative paths to fundraising, potentially shifting towards a digital asset treasury management company.
• Continue pre-clinical in-vitro and in-vivo studies for pipeline candidates, guided by AI insights.
• Seek third-party license deals for therapeutic assets following successful pre-clinical trials.
• Pursue further development, FDA approval, commercialization, and marketing of assets through agreements with third parties.
• Monitor and address ongoing legal proceedings with Strand Hanson Limited and St George Street Capital.
• Remediate identified material weaknesses in disclosure controls and procedures.
• Continue to evaluate novel artificial intelligence and cybernetics approaches to drug re-purposing, intellectual property, and asset selection.
• The trial in the Strand Hanson legal matter is expected to conclude with a determination in the first quarter of 2026.

Key Dates

Recommendation

The company's financial position is highly precarious, evidenced by a significant accumulated deficit of $47.0 million and an explicit 'substantial doubt' about its ability to continue as a going concern. While cash increased due to capital raises, this is offset by persistent and increasing net losses and negative operating cash flows. The substantial increase in general and administrative expenses, coupled with un-remediated material weaknesses in internal controls, points to operational inefficiencies and governance concerns. Ongoing legal disputes add further uncertainty and potential costs. Despite strategic shifts into AI biotech and digital assets, the fundamental financial health and control environment are severely compromised, making the stock a high-risk, speculative investment with significant downside potential.

Keywords

Biotech, Pharmaceutical Development, AI, Digital Assets, SEC Filing, 10-Q, Clinical Assets, Drug Repurposing, Nasdaq, Going Concern, Convertible Notes, Stock Incentive Plan, Research and Development, Corporate Governance